211 related articles for article (PubMed ID: 21607631)
1. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes.
Thomas MC; Söderlund J; Lehto M; Mäkinen VP; Moran JL; Cooper ME; Forsblom C; Groop PH;
Diabetologia; 2011 Oct; 54(10):2669-77. PubMed ID: 21607631
[TBL] [Abstract][Full Text] [Related]
2. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes.
Wadén JM; Dahlström EH; Elonen N; Thorn LM; Wadén J; Sandholm N; Forsblom C; Groop PH;
Diabetologia; 2019 Jul; 62(7):1268-1274. PubMed ID: 31127314
[TBL] [Abstract][Full Text] [Related]
3. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
Nin JW; Jorsal A; Ferreira I; Schalkwijk CG; Prins MH; Parving HH; Tarnow L; Rossing P; Stehouwer CD
Diabetes; 2010 Aug; 59(8):2027-32. PubMed ID: 20522598
[TBL] [Abstract][Full Text] [Related]
4. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
[TBL] [Abstract][Full Text] [Related]
5. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.
Humpert PM; Djuric Z; Kopf S; Rudofsky G; Morcos M; Nawroth PP; Bierhaus A
Cardiovasc Diabetol; 2007 Mar; 6():9. PubMed ID: 17343760
[TBL] [Abstract][Full Text] [Related]
6. Association of the receptor for advanced glycation end products (RAGE) -374 T/A gene polymorphism and circulating soluble RAGE with nephropathy in type 1 diabetic patients.
Abdel-Azeez HA; El-Okely AM
Egypt J Immunol; 2009; 16(1):95-106. PubMed ID: 20726326
[TBL] [Abstract][Full Text] [Related]
7. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
Melin EO; Dereke J; Hillman M
Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
[TBL] [Abstract][Full Text] [Related]
9. sRAGE and risk of diabetes, cardiovascular disease, and death.
Selvin E; Halushka MK; Rawlings AM; Hoogeveen RC; Ballantyne CM; Coresh J; Astor BC
Diabetes; 2013 Jun; 62(6):2116-21. PubMed ID: 23396398
[TBL] [Abstract][Full Text] [Related]
10. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study.
Nin JW; Ferreira I; Schalkwijk CG; Prins MH; Chaturvedi N; Fuller JH; Stehouwer CD;
Diabetologia; 2009 Apr; 52(4):705-14. PubMed ID: 19183936
[TBL] [Abstract][Full Text] [Related]
11. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
Nakashima A; Carrero JJ; Qureshi AR; Miyamoto T; Anderstam B; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2213-9. PubMed ID: 20847094
[TBL] [Abstract][Full Text] [Related]
12. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH
Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333
[TBL] [Abstract][Full Text] [Related]
13. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.
Kalousová M; Jáchymová M; Mestek O; Hodková M; Kazderová M; Tesar V; Zima T
Nephrol Dial Transplant; 2007 Jul; 22(7):2020-6. PubMed ID: 17347281
[TBL] [Abstract][Full Text] [Related]
14. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
15. Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
Thomas MC; Woodward M; Neal B; Li Q; Pickering R; Marre M; Williams B; Perkovic V; Cooper ME; Zoungas S; Chalmers J; Hillis GS;
Diabetes Care; 2015 Oct; 38(10):1891-7. PubMed ID: 26253728
[TBL] [Abstract][Full Text] [Related]
16. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
17. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels.
Gaens KH; Ferreira I; van der Kallen CJ; van Greevenbroek MM; Blaak EE; Feskens EJ; Dekker JM; Nijpels G; Heine RJ; 't Hart LM; de Groot PG; Stehouwer CD; Schalkwijk CG
J Clin Endocrinol Metab; 2009 Dec; 94(12):5174-80. PubMed ID: 19890027
[TBL] [Abstract][Full Text] [Related]
18. Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients.
Isoyama N; Machowska A; Qureshi AR; Yamamoto T; Anderstam B; Heimburger O; Barany P; Stenvinkel P; Lindholm B
Perit Dial Int; 2016; 36(3):269-76. PubMed ID: 26493750
[TBL] [Abstract][Full Text] [Related]
19. The role of soluble receptor for advanced glycation end-products (sRAGE) in the general population and patients with diabetes mellitus with a focus on renal function and overall outcome.
Steenbeke M; De Bruyne S; De Buyzere M; Lapauw B; Speeckaert R; Petrovic M; Delanghe JR; Speeckaert MM
Crit Rev Clin Lab Sci; 2021 Mar; 58(2):113-130. PubMed ID: 32669010
[TBL] [Abstract][Full Text] [Related]
20. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.
Pettersson-Fernholm K; Forsblom C; Hudson BI; Perola M; Grant PJ; Groop PH;
Diabetes; 2003 Mar; 52(3):891-4. PubMed ID: 12606536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
